Puretech Health (LON:PRTC)‘s stock had its “buy” rating restated by analysts at Numis Securities in a research note issued on Monday. They presently have a GBX 259 ($3.51) price target on the stock. Numis Securities’ target price suggests a potential upside of 44.69% from the company’s current price.
Several other analysts have also recently commented on PRTC. Peel Hunt raised their target price on Puretech Health from GBX 302 ($4.10) to GBX 313 ($4.24) and gave the stock a “buy” rating in a research report on Friday. Liberum Capital reaffirmed a “buy” rating and issued a GBX 248 ($3.36) target price on shares of Puretech Health in a research report on Friday. Jefferies Group reaffirmed a “buy” rating on shares of Puretech Health in a research report on Friday, November 17th. Finally, N+1 Singer reaffirmed a “buy” rating on shares of Puretech Health in a research report on Thursday, November 30th. Five equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of GBX 260.20 ($3.53).
Shares of Puretech Health (LON PRTC) opened at GBX 179 ($2.43) on Monday. The firm has a market capitalization of $425.00 and a price-to-earnings ratio of -994.44. Puretech Health has a one year low of GBX 110 ($1.49) and a one year high of GBX 183.50 ($2.49).
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with MarketBeat.com's FREE daily email newsletter.